May 8, 2018

Philips expands its Sleep & Respiratory Care portfolio with the acquisition of NightBalance

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has acquired NightBalance, a digital health scale-up company based in the Netherlands, that has developed an innovative, easy to use device to treat positional obstructive sleep apnea and positional snoring. Financial details of the transaction were not disclosed.

NightBalance’s Sleep Position Trainer (SPT) was designed as a comfortable and easy to use treatment alternative for people who suffer from positional obstructive sleep apnea. The SPT gently prompts them not to sleep on their back, avoiding the apneas from occurring during sleep. The SPT is CE-marked and is currently marketed in select countries in Europe [1].

NightBalance offers a unique, patient friendly solution to treat positional obstructive sleep apnea and positional snoring that is highly complementary to our current offerings.

John Frank

Business Leader Sleep & Respiratory Care at Philips

“NightBalance offers a unique, patient friendly solution to treat positional obstructive sleep apnea and positional snoring that is highly complementary to our current offerings," said John Frank, Business Leader Sleep & Respiratory Care at Philips. "This acquisition will help us further expand our leadership position in the growing home care market, and our ability to deliver integrated solutions that drive efficiencies and improved outcomes.”

“We founded NightBalance in 2009 with the ambition to improve the lives of positional apnea patients worldwide”, said Eline Vrijland-van Beest, CEO of NightBalance. “I am proud that our innovation is in good hands with Philips. Their strength in connected sleep therapy solutions and global reach will accelerate the accessibility of the Sleep Position Trainer”.

Obstructive sleep apnea is a serious condition in which breathing pauses and restarts during sleep. When most of these pauses occur when a person is lying on his or her back, it is called positional obstructive sleep apnea. Philips already offers a broad range of care solutions for people living with obstructive sleep apnea. This includes the award-winning Dream Family comprising DreamWear, a comprehensive portfolio of advanced mask designs, DreamStation, a CPAP therapy [2] system connecting patients and care teams, and DreamMapper, an application that helps patients adjust to sleep therapy and compliance.

[1] SPT is not available in the US

[2] Continuous Positive Airway Pressure therapy

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2017 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Click here to read more Click here to read less

Forward-looking statements

This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Click here to read more Click here to read less